ACP 001

Drug Profile

ACP 001

Alternative Names: ACP 011; ACP-001; TransCon growth hormone; TransCon PEG growth hormone; TransCon PEG hGH; TransCon PEG somatropin

Latest Information Update: 23 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ascendis Pharma
  • Class Growth hormones; Hormonal replacements; Polyethylene glycols
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Somatotropin deficiency

Most Recent Events

  • 16 Nov 2017 Ascendis Pharma plans the enliGHten phase III trial for Somatotropin-deficiency (In adolescents, In children, In infants, In adults) in USA (NCT03344458)
  • 16 Nov 2017 Phase-III clinical trials in Somatotropin deficiency (In infants, In children, In adolescents) in New Zealand (SC) (NCT03305016)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Somatotropin-deficiency(In volunteers) in Canada (SC, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top